BT-6107

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ***Kode Matakuliah:******BT-6107*** | ***Bobot sks:2SKS*** | ***Semester:GANJIL*** | ***KK / Unit Penanggung Jawab:***  | ***Sifat:***Pilihan |
| ***Nama Matakuliah*** | Gene terapi berbasis molekul |
| Molecular based Therapy Gene |
| ***Silabus Ringkas*** | [*Uraian ringkas silabus matakuliah dalam Bahasa Indonesia (maksimum 30 kata)*] |
| [*Uraian ringkas silabus matakuliah dalam Bahasa Indonesia (maksimum 30 kata)*] |
| ***Silabus Lengkap*** | [*Uraian lengkap silabus matakuliah dalam Bahasa Indonesia (maksimum 100 kata)*] |
| [*Uraian lengkap silabus matakuliah dalam Bahasa Inggris (maksimum 100 kata)*] |
| ***Luaran (Outcomes)*** | [*Uraian hasil/luaran (kompetensi mahasiswa) yang diharapkan setelah penyelesaian matakuliah ini*] |
| ***Matakuliah Terkait*** | [*Kode dan Nama Matakuliah*] | [*Prasyarat, bersamaan, terlarang*] |
| [*Kode dan Nama Matakuliah*] | [*Prasyarat, bersamaan, terlarang*] |
| ***Kegiatan Penunjang*** | [*Praktikum, kerja lapangan, dsb.*] |
| ***Pustaka*** | [*Penulis, Judul, Edisi, Penerbit, Tahun terbit*] ([*Pustaka utama/alternatif/pendukung*]) |
| [*Penulis, Judul, Edisi, Penerbit, Tahun terbit*] ([*Pustaka utama/alternatif/pendukung*]) |
| [*Penulis, Judul, Edisi, Penerbit, Tahun terbit*] ([*Pustaka utama/alternatif/pendukung*]) |
| ***Panduan Penilaian*** | [*Termasuk jenis dan bentuk penilaian*] |
| ***Catatan Tambahan*** |  |

1. Non-Viral Gene Therapy 1

*Sean M. Sullivan*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 1

2. Plasmid DNA . . . . . . . . . . . . . . . . . . . . . . . 3

2.1 Plasmid DNA Manufacture . . . . . . . . . . . . . 5

3. Plasmid DNA Gene Transfer Methods . . . . . . . . . . 6

3.1 Plasmid DNA or “Naked DNA” as a Gene Delivery

System . . . . . . . . . . . . . . . . . . . . . . . 6

3.1.1 Electroporation of Naked DNA . . . . . . . 8

3.1.2 Sonoporation of Naked DNA . . . . . . . . 9

3.2 Plasmid DNA Formulations . . . . . . . . . . . . 9

3.2.1 Cationic Lipids . . . . . . . . . . . . . . . 9

3.2.1.1 *In vitro* transfection . . . . . . . . 10

3.2.1.2 Systemic *in vivo* gene transfer . . . 11

3.2.1.3 Local administration of cationic

lipid/pDNA transfection

complexes . . . . . . . . . . . . . 12

3.3 Polymer . . . . . . . . . . . . . . . . . . . . . . . 14

3.3.1 Cationic Polymers . . . . . . . . . . . . . . 14

3.3.2 Neutral Polymer . . . . . . . . . . . . . . . 15

Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 17

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

ix

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*A Guide to Human Gene Therapy*

2. Adenoviral Vectors 21

*Stuart A. Nicklin and Andrew H. Baker*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 21

2. Adenoviral Capsid Structure . . . . . . . . . . . . . . . 22

3. Adenoviral Cell Entry . . . . . . . . . . . . . . . . . . . 23

4. Production of Adenoviral Vectors . . . . . . . . . . . . . 24

5. Production of Targeted Adenoviral Vectors . . . . . . . . 26

6. Gene Therapy Applications . . . . . . . . . . . . . . . . 28

7. Immune Responses to Ad Vectors . . . . . . . . . . . . 30

8. Safety and Regulatory Issues . . . . . . . . . . . . . . . 32

9. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 33

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 33

3. Retroviral Vectors and Integration Analysis 37

*Cynthia C. Bartholomae, Romy Kirsten, Hanno Glimm,*

*Manfred Schmidt and Christof von Kalle*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 37

2. Design, Production and Mechanism of Transduction . . . 38

3. *In vivo* Application . . . . . . . . . . . . . . . . . . . . 41

4. Side Effects in Retroviral Gene Therapy . . . . . . . . . 42

4.1 Distribution of Retroviral Integration Sites

in the Cellular Genome . . . . . . . . . . . . . . . 42

4.2 Side Effects in Clinical and Preclinical Gene

Therapy Studies . . . . . . . . . . . . . . . . . . . 45

5. New Strategies for Vector Biosafety in Gene Therapy . . 47

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 49

4. Lentiviral Vectors 53

*Janka Mátrai, Marinee K. L. Chuah*

*and Thierry VandenDriessche*

1. Basic Viral Biology . . . . . . . . . . . . . . . . . . . . 53

2. Vector Design and Production . . . . . . . . . . . . . . 56

2.1 Vector Development . . . . . . . . . . . . . . . . 56

2.2 Vector Production . . . . . . . . . . . . . . . . . . 58

x

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*Contents*

3. Gene Transfer Concepts and Potential Applications . . . 59

3.1 Target Cells and Diseases . . . . . . . . . . . . . . 59

3.2 Pseudotyping . . . . . . . . . . . . . . . . . . . . 59

3.3 Cell Type Specific Targeting . . . . . . . . . . . . 60

3.4 Integration-Defective Lentiviral Vectors . . . . . . 60

4. Immune Consequences . . . . . . . . . . . . . . . . . . 62

5. Safety Issues . . . . . . . . . . . . . . . . . . . . . . . 63

6. Conclusions and Perspectives . . . . . . . . . . . . . . . 64

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 64

5. Herpes Simplex Virus Vectors 69

*William F. Goins, David M. Krisky, James B. Wechuck,*

*Darren Wolfe, Justus B. Cohen and Joseph C. Glorioso*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 69

2. HSVBiology in the Design of Replication DefectiveVectors 74

3. HSV Vector Design Technology . . . . . . . . . . . . . 77

4. Gene Transfer/Therapy Applications . . . . . . . . . . . 79

5. Immunology . . . . . . . . . . . . . . . . . . . . . . . 80

6. Safety and Regulatory Issues . . . . . . . . . . . . . . . 81

7. Summary . . . . . . . . . . . . . . . . . . . . . . . . . 81

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 82

6. Adeno-Associated Viral (AAV) Vectors 87

*Nicholas Muzyczka*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 87

2. Biology of AAV . . . . . . . . . . . . . . . . . . . . . . 88

3. Vector Technology . . . . . . . . . . . . . . . . . . . . 93

4. Vector Characteristics *In Vivo* . . . . . . . . . . . . . . . 96

5. Next Generation Vectors . . . . . . . . . . . . . . . . . 98

6. Conclusions and Outlook . . . . . . . . . . . . . . . . . 99

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 99

xi

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*A Guide to Human Gene Therapy*

7. Regulatory RNA in Gene Therapy 103

*Alfred. S. Lewin*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 103

2. Delivery of Therapeutic RNAs . . . . . . . . . . . . . . 106

3. Ribozymes . . . . . . . . . . . . . . . . . . . . . . . . 109

4. RNAi for Gene Therapy . . . . . . . . . . . . . . . . . 111

5. Gene Therapy Using miRNA . . . . . . . . . . . . . . . 114

6. Aptamers, Decoys and Bi-Functional RNAs . . . . . . . 115

7. Modification of Cis-Acting Regulatory

RNA Sequences . . . . . . . . . . . . . . . . . . . . . . 116

8. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 119

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 120

8. DNA Integrating Vectors (Transposon, Integrase) 123

*Lauren E. Woodard and Michele P. Calos*

1. Basic Vector Biology . . . . . . . . . . . . . . . . . . . 123

1.1 Transposon Systems . . . . . . . . . . . . . . . . 124

1.2 Integrase Systems . . . . . . . . . . . . . . . . . . 126

2. Vector Design and Production . . . . . . . . . . . . . . 128

2.1 Design of Transposon Systems . . . . . . . . . . . 128

2.2 Design of Integrase Systems . . . . . . . . . . . . 128

2.3 Production of Plasmid DNA . . . . . . . . . . . . 129

3. Gene Transfer Protocols and Potential Applications . . . 130

3.1 Hepatocyte Transfection via Hydrodynamic

Injection . . . . . . . . . . . . . . . . . . . . . . . 130

3.2 Lipophilic Complexes to Transfect Endothelial

Cells and Glioblastoma . . . . . . . . . . . . . . . 131

3.3 Direct DNA Injection and Electroporation

to Target Muscle, Retina, and Joints . . . . . . . . 131

3.4 Integration into Cultured Cells for

*Ex vivo* Gene Therapy . . . . . . . . . . . . . . . 131

4. Immunology . . . . . . . . . . . . . . . . . . . . . . . 132

xii

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*Contents*

5. Safety and Regulatory Issues . . . . . . . . . . . . . . . 133

5.1 Integration Profiles and Associated Hazards . . . . 133

5.2 Efforts to Enhance Integration Specificity . . . . . 133

5.3 Effects on Tumor Latency in Mouse Models

of Cancer . . . . . . . . . . . . . . . . . . . . . . 134

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 135

9. Homologous Recombination and Targeted Gene

Modification for Gene Therapy 139

*Matthew Porteus*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 139

2. Problems with Using Gene Targeting by Homologous

Recombination . . . . . . . . . . . . . . . . . . . . . . 140

3. Homologous Recombination in Embryonic

Stem Cells . . . . . . . . . . . . . . . . . . . . . . . . . 141

4. Homologous Recombination using

Adeno-Associated Virus . . . . . . . . . . . . . . . . . 144

5. Site-Specific Modification of the Genome using

Double-Strand Breaks . . . . . . . . . . . . . . . . . . 144

6. Double-Strand Break Repair . . . . . . . . . . . . . . . 144

7. Double-Strand Break Induced Homologous

Recombination . . . . . . . . . . . . . . . . . . . . . . 146

8. Re-design of Homing Endonucleases to Recognize

New Target Sites . . . . . . . . . . . . . . . . . . . . . 146

9. Development of Zinc Finger Nucleases . . . . . . . . . 147

10. Using Zinc Finger Nucleases to Stimulate

Gene Targeting . . . . . . . . . . . . . . . . . . . . . . 147

11. Using Zinc Finger Nucleases to Site-Specifically Modify

Genes by Mutagenic Non-Homologous

End-Joining . . . . . . . . . . . . . . . . . . . . . . . . 149

12. Strategies of Zinc Finger Nuclease Design . . . . . . . . 151

13. Aspects of Zinc Finger Binding Sites and Structure

of Zinc Finger Nucleases . . . . . . . . . . . . . . . . . 153

14. Zinc Finger Nuclease Toxicity: Measuring

and Minimizing . . . . . . . . . . . . . . . . . . . . . . 154

xiii

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*A Guide to Human Gene Therapy*

15. The Challenge of Delivery . . . . . . . . . . . . . . . . 156

16. Future Directions and Promise of Homologous

Recombination as a Gene Correction Approach

to Gene Therapy . . . . . . . . . . . . . . . . . . . . . 157

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 157

10. Gene Switches for Pre-Clinical Studies in Gene Therapy 163

*Caroline Le Guiner, Knut Stieger, Alice Toromanoff,*

*Fabienne Rolling, Philippe Moullier and Oumeya Adjali*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 163

2. Rapamycin-Dependent Regulatable System . . . . . . . 165

2.1 Molecular Mechanisms Involved in Transgene

Regulation . . . . . . . . . . . . . . . . . . . . . 165

2.2 Pharmacology of Rapamycin . . . . . . . . . . . . 166

2.3 Translation Development of the Rapamycin

Dependent Regulation System . . . . . . . . . . . 166

3. Tetracycline-Dependent Regulatable Systems . . . . . . 168

3.1 Molecular Mechanisms Involved in Transgene

Regulation . . . . . . . . . . . . . . . . . . . . . 168

3.2 Pharmacology of Doxycycline (Dox) . . . . . . . . 171

3.3 Translational Development of Tet-dependant

Regulation Systems . . . . . . . . . . . . . . . . . 171

4. Other Regulatable Systems . . . . . . . . . . . . . . . . 175

5. General Conclusions . . . . . . . . . . . . . . . . . . . 177

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 177

11. Gene Therapy for Central Nervous System Disorders 181

*Deborah Young and Patricia A. Lawlor*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 181

2. Gene Therapy for Parkinson’s Disease . . . . . . . . . . 182

3. Gene Therapy for Temporal Lobe Epilepsy . . . . . . . 186

4. Huntington’s Disease Gene Therapy . . . . . . . . . . . 187

5. Amyotrophic Lateral Sclerosis (ALS) . . . . . . . . . . 189

6. Gene Therapy for Canavan Disease . . . . . . . . . . . . 190

xiv

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*Contents*

7. Gene Therapy for Alzheimer’s Disease . . . . . . . . . . 191

8. Conclusions and Outlook . . . . . . . . . . . . . . . . . 193

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 194

12. Gene Therapy of Hemoglobinopathies 197

*Angela E. Rivers and Arun Srivastava*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 198

2. *β*-Thalassemia . . . . . . . . . . . . . . . . . . . . . . 198

3. Sickle Cell Disease . . . . . . . . . . . . . . . . . . . . 199

4. Gene Therapy . . . . . . . . . . . . . . . . . . . . . . . 200

4.1 Oncoretroviral Vector-Mediated Globin

Gene Transfer . . . . . . . . . . . . . . . . . . . . 202

4.2 Lentiviral Vector-Mediated Globin

Gene Transfer . . . . . . . . . . . . . . . . . . . . 203

4.3 Adeno-Associated Viral Vector-Mediated Globin

Gene Transfer . . . . . . . . . . . . . . . . . . . . 204

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 208

13. Gene Therapy for Primary Immunodeficiencies 213

*Aisha Sauer, Barbara Cassani and Alessandro Aiuti*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 214

2. Adenosine Deaminase (ADA)-deficient SCID . . . . . . 215

3. X-linked Severe Combined Immunodeficiency

(SCID-X1) . . . . . . . . . . . . . . . . . . . . . . . . 218

4. Gene Therapy for Other SCIDs . . . . . . . . . . . . . . 220

4.1 V(D)J Recombination Defects . . . . . . . . . . . 220

4.2 Purine Nucleoside Phosphorylase (PNP)

Deficiency . . . . . . . . . . . . . . . . . . . . . . 222

4.3 Janus Kinase 3 (Jak3) Deficiency . . . . . . . . . . 222

4.4 IL-7R Deficiency . . . . . . . . . . . . . . . . . . 223

4.5 Zeta Associated 70 kDa Phosphoprotein

(ZAP-70) Deficiency . . . . . . . . . . . . . . . . 223

5. Wiskott-Aldrich-Syndrome (WAS) . . . . . . . . . . . . 224

6. Chronic Granulomatous Disease . . . . . . . . . . . . . 225

7. Conclusions and Outlook . . . . . . . . . . . . . . . . . 227

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 228

xv

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*A Guide to Human Gene Therapy*

14. Gene Therapy for Hemophilia 233

*David Markusic, Babak Moghimi and Roland Herzog*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 233

2. Limitations of Hemophilia TreatmentWith

Coagulation Factor Concentrates or Recombinant

Coagulation Factors . . . . . . . . . . . . . . . . . . . . 235

3. Gene Transfer for Correction of Hemophilia . . . . . . . 236

3.1 *Ex Vivo* Gene Transfer of F.VIII and F.IX . . . . . 236

3.2 *In Vivo* Gene Transfer of F.VIII and F.IX . . . . . . 237

4. AAV is a Preferred Gene Therapy Vector for *In Vivo*

Gene Transfer to Correct of Hemophilia . . . . . . . . . 238

5. Immunological Considerations for Efficient F.IX

Gene Transfer . . . . . . . . . . . . . . . . . . . . . . . 239

6. Advancements from Small and Large Animal Models

of Hemophilia . . . . . . . . . . . . . . . . . . . . . . . 242

6.1 Murine Hemophilia Models . . . . . . . . . . . . 242

6.2 Canine Hemophilia Models . . . . . . . . . . . . . 242

7. Gene Therapy Trials for Hemophilia Past, Present, and

Future . . . . . . . . . . . . . . . . . . . . . . . . . . . 244

8. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 245

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 246

15. Gene Therapy for Obesity and Diabetes 251

*Sergei Zolotukhin and Clive H. Wasserfall*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 251

2. Understanding Obesity: WhyWe Get Fat . . . . . . . . 252

2.1 Genetic Factors: Human Obesity Gene Map . . . . 252

2.2 Environmental Factors: The Big Two and Other

Causal Contributors . . . . . . . . . . . . . . . . . 253

3. General Strategies in Gene Therapy for Obesity . . . . . 253

4. Gene Delivery Vehicles . . . . . . . . . . . . . . . . . . 255

5. Gene Targets for Obesity . . . . . . . . . . . . . . . . . 255

5.1 Leptin . . . . . . . . . . . . . . . . . . . . . . . . 255

5.2 Neurocytokines . . . . . . . . . . . . . . . . . . . 256

xvi

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*Contents*

5.3 AMP-Activated Protein Kinase (AMPK) . . . . . . 256

5.4 Adiponectin . . . . . . . . . . . . . . . . . . . . . 257

5.5 Wnt-10b . . . . . . . . . . . . . . . . . . . . . . . 257

5.6 Obesity Gene Menu à la Carte . . . . . . . . . . . 258

5.7 Obesity and Diabetes . . . . . . . . . . . . . . . . 259

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 260

16. Gene Therapy for Duchenne Muscular

Dystrophy 261

*Takashi Okada and Shin’ichi Takeda*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 261

1.1 Background of Duchenne Muscular Dystrophy . . 261

2. Gene-replacement Strategies using Virus Vectors . . . . 262

2.1 Choice of Vector . . . . . . . . . . . . . . . . . . 262

2.2 Modification of the Dystrophin Gene

and Promoter . . . . . . . . . . . . . . . . . . . . 264

2.3 Use of Surrogate Genes . . . . . . . . . . . . . . . 266

3. AAV-Mediated Transduction of Animal Models . . . . . 266

3.1 Vector Production . . . . . . . . . . . . . . . . . . 266

3.2 Animal Models for the Gene

Transduction Study . . . . . . . . . . . . . . . . . 267

3.3 Immunological Issues of rAAV . . . . . . . . . . . 268

3.4 Intravascular Vector Administration

by Limb Perfusion . . . . . . . . . . . . . . . . . 269

3.5 Global Muscle Therapies . . . . . . . . . . . . . . 269

4. Safety and Potential Impact of Clinical Trials . . . . . . 270

5. Development of Alternative Strategies . . . . . . . . . . 271

5.1 Design of Read-through Drugs . . . . . . . . . . . 271

5.2 Modification of mRNA Splicing . . . . . . . . . . 272

5.3 *Ex Vivo* Gene Therapy . . . . . . . . . . . . . . . 272

6. Future Perspectives . . . . . . . . . . . . . . . . . . . . 273

6.1 Pharmacological Intervention . . . . . . . . . . . . 273

6.2 Capsid Modification . . . . . . . . . . . . . . . . 273

7. Conclusions and Outlook . . . . . . . . . . . . . . . . . 273

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 274

xvii

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*A Guide to Human Gene Therapy*

17. Cancer Gene Therapy 279

*Kirsten A.K. Weigel-Van Aken*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 280

2. Targeting the Tumor Cell . . . . . . . . . . . . . . . . . 280

2.1 DNA Electroporation . . . . . . . . . . . . . . . . 280

2.2 Non-Oncolytic Viral Vectors . . . . . . . . . . . . 281

2.2.1 Retrovirus . . . . . . . . . . . . . . . . . . 281

2.2.2 Lentivirus . . . . . . . . . . . . . . . . . . 282

2.3 Oncolytic Viruses . . . . . . . . . . . . . . . . . . 282

2.3.1 Herpesvirus . . . . . . . . . . . . . . . . . 283

2.3.2 Adenovirus . . . . . . . . . . . . . . . . . . 283

2.3.3 Poxvirus . . . . . . . . . . . . . . . . . . . 284

2.3.4 Measles virus . . . . . . . . . . . . . . . . 285

2.3.5 Vesicular stomatitis virus . . . . . . . . . . 285

3. Targeting the Immune System . . . . . . . . . . . . . . 286

3.1 Cancer Vaccines . . . . . . . . . . . . . . . . . . . 287

3.1.1 Vaccinia virus . . . . . . . . . . . . . . . . 287

3.1.2 Lentivirus . . . . . . . . . . . . . . . . . . 287

3.1.3 Adenovirus . . . . . . . . . . . . . . . . . . 288

3.1.4 Parvoviruses . . . . . . . . . . . . . . . . . 288

3.2 Mesenchymal Stem Cells (MSC)

as Delivery Vehicles . . . . . . . . . . . . . . . . 288

3.3 Adoptive T Cell Transfer . . . . . . . . . . . . . . 288

4. Targeting the Tumor Microenvironment . . . . . . . . . 289

5. Challenges and Risks of Cancer Gene Therapy . . . . . 289

6. Novel Strategies . . . . . . . . . . . . . . . . . . . . . . 290

6.1 Prime/Boost Regimens . . . . . . . . . . . . . . . 290

6.2 Immune Cells as Carriers for Viruses . . . . . . . . 290

7. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . 291

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 291

18. Gene Therapy for Autoimmune Disorders 295

*Daniel F. Gaddy, Melanie A. Ruffner and Paul D. Robbins*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 295

2. Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . 296

xviii

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*Contents*

2.1 Background . . . . . . . . . . . . . . . . . . . . . 296

2.2 Existing Therapies . . . . . . . . . . . . . . . . . 296

2.3 Target Tissues and Routes of Delivery . . . . . . . 297

2.3.1 Local RA Gene Therapy . . . . . . . . . . . 297

2.3.2 Systemic RA Gene Therapy . . . . . . . . . 297

2.4 Immunomodulation . . . . . . . . . . . . . . . . . 298

2.5 Overview of Preclinical Gene Therapy Studies . . 299

2.6 Overview of Clinical Gene Therapy Studies . . . . 301

3. Type I Diabetes Mellitus . . . . . . . . . . . . . . . . . 301

3.1 Background . . . . . . . . . . . . . . . . . . . . . 301

3.2 Existing Therapies . . . . . . . . . . . . . . . . . 302

3.3 Target Tissues and Routes of Delivery . . . . . . . 303

3.4 Immunomodulation . . . . . . . . . . . . . . . . . 303

3.5 Overview of Preclinical Gene Therapy Studies . . 305

3.6 Overview of Clinical Gene Therapy Studies . . . . 306

4. Conclusions and Outlook . . . . . . . . . . . . . . . . . 307

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 308

19. Gene Therapy for Inherited Metabolic Storage Diseases 311

*Cathryn Mah*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 311

2. Lysosomal Storage Diseases . . . . . . . . . . . . . . . 312

3. Glycogen Storage Diseases . . . . . . . . . . . . . . . . 314

4. Animal Models . . . . . . . . . . . . . . . . . . . . . . 315

5. Cross-Correction Strategies . . . . . . . . . . . . . . . . 319

6. Direct Correction of Target Tissues . . . . . . . . . . . . 321

7. Conclusions and Outlook . . . . . . . . . . . . . . . . . 324

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 324

20. Retinal Diseases 327

*Shannon E. Boye, Sanford L. Boye and William W. Hauswirth*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 327

2. Rod and Cone Photoreceptors . . . . . . . . . . . . . . 330

3. Cone Photoreceptors . . . . . . . . . . . . . . . . . . . 333

4. Retinal Ganglion Cells . . . . . . . . . . . . . . . . . . 335

xix

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*A Guide to Human Gene Therapy*

5. Retinal Pigment Epithelium . . . . . . . . . . . . . . . 337

6. LCA2 Gene Therapy, a Perspective on Translational

Research . . . . . . . . . . . . . . . . . . . . . . . . . 339

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 342

21. A Brief Guide to Gene Therapy Treatments

for Pulmonary Diseases 345

*Ashley T. Martino, Christian Mueller*

*and Terence R. Flotte*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 345

2. Common Disorders . . . . . . . . . . . . . . . . . . . . 346

2.1 Cystic Fibrosis . . . . . . . . . . . . . . . . . . . 346

2.2 Alpha-1 Antitrypsin (A1AT) . . . . . . . . . . . . 348

3. Development of Viral Vectors for Lung Disease . . . . . 348

3.1 Adenoviral Vectors . . . . . . . . . . . . . . . . . 349

3.2 Adeno-Associated Viral Vectors . . . . . . . . . . 349

3.3 Early Conclusions . . . . . . . . . . . . . . . . . 349

4. Enhancing Efficiency . . . . . . . . . . . . . . . . . . . 350

4.1 Alternative AAV Viral Vector Serotypes . . . . . . 350

4.1.1 Addition of Expression Enhancing

Elements . . . . . . . . . . . . . . . . . . . 351

4.2 Adenoviral Vectors . . . . . . . . . . . . . . . . . 351

4.3 Physiological Hurdles in the Lung

Environment . . . . . . . . . . . . . . . . . . . . 352

5. Non-Viral Vectors . . . . . . . . . . . . . . . . . . . . . 352

5.1 Cationic Liposomes . . . . . . . . . . . . . . . . . 352

5.2 Compacted DNA Nanoparticles . . . . . . . . . . 353

6. Gene Therapy Development for Alpha-1

Anti-trypsin . . . . . . . . . . . . . . . . . . . . . . . . 353

7. Lung Cancer Gene Therapy Development . . . . . . . . 354

8. Cystic Fibrosis Animal Models . . . . . . . . . . . . . . 355

9. Cell-Based Therapy for Cystic Fibrosis . . . . . . . . . 356

10. Conclusion and Outlooks . . . . . . . . . . . . . . . . . 357

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 358

xx

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

*Contents*

22. Cardiovascular Disease 361

*Darin J. Falk, Cathryn S. Mah and Barry J. Byrne*

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . 361

2. Therapeutic Targets . . . . . . . . . . . . . . . . . . . . 362

2.1 Congenital Heart Disease . . . . . . . . . . . . . . 362

2.2 Coronary Artery Disease and Ischemia/

Reperfusion Injury . . . . . . . . . . . . . . . . . 365

2.3 Oxidative Stress . . . . . . . . . . . . . . . . . . . 365

2.4 Antioxidants . . . . . . . . . . . . . . . . . . . . 366

2.5 Cardiac Contractility . . . . . . . . . . . . . . . . 367

3. Animal Models . . . . . . . . . . . . . . . . . . . . . . 367

4. Vector Delivery . . . . . . . . . . . . . . . . . . . . . . 368

5. Conclusions and Outlook . . . . . . . . . . . . . . . . . 374

Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . 374

References . . . . . . . . . . . . . . . . . . . . . . . . . . . 374

Index 379

xxi

A Guide to Human Gene Therapy Downloaded from www.worldscientific.com

by 169.147.3.25 on 02/07/13. For personal use only.

This

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ***Mg#*** | ***Topik*** | ***Sub Topik*** | ***Capaian Belajar Mahasiswa*** | ***Sumber Materi*** |
| *1* | Gene transfer  | Pendahuluan | [*Uraikan capaian spesifik topik dengan merujuk kepada capaian matakuliah*] | [*Uraikan rujukan terhadap pustaka (bab, sub-bab)*] |
| *2* | *Vector berbasis plasmid dan nanopartikel* |  |  |  |
| *3* | *Transposon dan vector teringrasi* |  |  |  |
| *4* | *Vector Retrovirus dan Lentivirus* |  |  |  |
| *5* | *Vektor adenovirus* |  |  |  |
| *6* | Adeno-associated viral vectors I |  |  |  |
| *7* | *UTS* |  |  |  |
| *8* | *Gene switches* |  |  |  |
| *9* | *Regulatory RNA* |  |  |  |
| *10* | *DNAIntegrating Vectors (transposon, integrase)* |  |  |  |
| *11* | *Homologous recombination dan modifikasi targeted gene* |  |  |  |
| *12* | *Teknologi stem cell termodifikasi genetik* |  |  |  |
| *13* | *Magnetofection*  |  |  |  |
| *14* | *Biolistic dan Photochemical internalization* |  |  |  |
| *15* | *Makalah dan Presentasi*  |  |  |  |
| *16* | *UAS* |  |  |  |

Uts 35

Uas 35

Assignment 10

Paper 20